doi:10.3969/j.issn.1004-583X.2024.04.010

Abstract

CLC Number:

R657.34

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.04.010

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I4/352

Figures/Tables 1

References 40

[1]	Tamura Y, Tamura Y, Taniguchi Y, et al. Current clinical understanding and effectiveness of portopulmonary hypertension treatment[J]. Front Med (Lausanne), 2023, 10:1142836.
[2]	Jasso-Baltazar EA, Peña-Arellano GA, Aguirre-Valadez J, et al. Portopulmonary hypertension: An updated review[J]. Transplant Direct, 2023, 9(8):e1517. doi: 10.1097/TXD.0000000000001517 pmid: 37492078
[3]	Sithamparanathan S, Nair A, Thirugnanasothy L, et al. Survival in portopulmonary hypertension: Outcomes of the united kingdom national pulmonary arterial hypertension registry[J]. J Heart Lung Transplant, 2017, 36(7):770-779.
[4]	Navarro-Vergara DI, Roldan-Valadez E, Cueto-Robledo G, et al. Portopulmonary hypertension: Prevalence, clinical and hemodynamic features[J]. Curr Probl Cardiol, 2021, 46(3):100747.
[5]	Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites[J]. Gut, 2003, 52(9):1355-1362. doi: 10.1136/gut.52.9.1355 pmid: 12912870
[6]	Weinfurtner K, Forde K. Hepatopulmonary syndrome and portopulmonary hypertension: Current status and implications for liver transplantation[J]. Curr Hepatol Rep, 2020, 19(3):174-185. doi: 10.1007/s11901-020-00532-y pmid: 32905452
[7]	Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38(4):570-580. doi: 10.1111/liv.13589 pmid: 28921803
[8]	Thomas C, Glinskii V, de Jesus Perez V, et al. Portopulmonary hypertension: From bench to bedside[J]. Front Med (Lausanne), 2020, 7:569413.
[9]	Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: Clinical studies update[J]. Gut Liver, 2021, 15(5):666-676. doi: 10.5009/gnl20032 pmid: 33071239
[10]	Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease[J]. Am J Respir Crit Care Med, 2009, 179(9):835-842.
[11]	Al-Naamani N, Krowka MJ, Forde KA, et al. Estrogen signaling and portopulmonary hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)[J]. Hepatology, 2021, 73(2):726-737.
[12]	Castaño G, Sookoian S. Female sex and autoimmune hepatitis and the risk of portopulmonary hypertension[J]. Hepatology, 2008, 48(6):2090. doi: 10.1002/hep.22599 pmid: 19026001
[13]	Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension[J]. Hepatology, 2008, 48(1):196-203. doi: 10.1002/hep.22275 pmid: 18537192
[14]	DuBrock HM, Cartin-Ceba R, Channick RN, et al. Sex differences in portopulmonary hypertension[J]. Chest, 2021, 159(1):328-336. doi: 10.1016/j.chest.2020.07.081 pmid: 32798521
[15]	Shao Y, Yin X, Qin T, et al. Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: A case-control study[J]. Biomed Res Int, 2021, 2021:5595614.
[16]	Miyasaka A, Yoshida Y, Suzuki A, et al. A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection[J]. Clin J Gastroenterol, 2020, 13(1):90-96. doi: 10.1007/s12328-019-01016-3 pmid: 31292842
[17]	Kawanaka H, Akahoshi T, Kinjo N, et al. Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension[J]. Br J Surg, 2014, 101(12):1585-1593. doi: 10.1002/bjs.9622 pmid: 25200126
[18]	Segraves JM, Cartin-Ceba R, Leise MD, et al. Relationship between portopulmonary hypertension and splenectomy: Mayo clinic experience and review of published works[J]. Hepatol Res, 2018, 48(3):e340-e346.
[19]	Huang L, Li W, Yang T, et al. Association between splenectomy and portal hypertension in the development of pulmonary hypertension[J]. Pulm Circ, 2020, 10(1):2045894019895426.
[20]	Korbitz PM, Gallagher JP, Samant H, et al. Performance of echocardiography for detection of portopulmonary hypertension among liver transplant candidates: Meta-analysis[J]. Clin Transplant, 2020, 34(11):e13995.
[21]	Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: An analysis of cutoff values[J]. Liver Transpl, 2013, 19(6):602-610.
[22]	Yin X, Shao Y, Zhang Y, et al. Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: A meta-analysis[J]. PeerJ, 2020, 8:e9243.
[23]	Nikolic I, Yung LM, Yang P, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension[J]. Am J Respir Crit Care Med, 2019, 199(7):891-902.
[24]	Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension[J]. Cell Mol Life Sci, 2017, 74(16):2979-2995. doi: 10.1007/s00018-017-2510-4 pmid: 28447104
[25]	DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, et al. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension[J]. Pulmonary circulation, 2016, 6(4):498-507. doi: 10.1086/688489 pmid: 28090291
[26]	Hayashi R, Kogiso T, Kikuchi N, et al. Portopulmonary hypertension and the risk of high right ventricular systolic pressure in liver transplant candidates[J]. PLoS ONE, 2022, 17(4):e0267125.
[27]	Yoshimaru K, Matsuura T, Takahashi Y, et al. The efficacy of serum brain natriuretic peptide for the early detection of portopulmonary hypertension in biliary atresia patients before liver transplantation[J]. Pediatr Transplant, 2018, 22(5):e13203.
[28]	Zhang R, Li T, Shao Y, et al. Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis[J]. Front Pharmacol, 2022, 13:991568.
[29]	Tokushige K, Kogiso T, Egawa H. Current therapy and liver transplantation for portopulmonary hypertension in Japan[J]. J Clin Med, 2023, 12(2):562.
[30]	Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): A multicentre, randomised, double-blind, placebo-controlled, phase 4 trial[J]. Lancet Respir Med, 2019, 7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8 pmid: 31178422
[31]	Krowka M, Cottreel E, Hoeper MM, et al. Macitentan improves risk categorization for liver transplant mortality in patients with portopulmonary hypertension: A PORTICO study post hoc analysis[J]. Liver Transpl, 2020, 26(7):935-940.
[32]	Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial[J]. J Heart Lung Transplant, 2020, 39(5):464-472.
[33]	Rossi R, Talarico M, Schepis F, et al. Effects of sildenafil on right ventricle remodelling in portopulmonary hypertension[J]. Pulm Pharmacol Ther, 2021, 70:102071.
[34]	Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management[J]. J Hepatol, 2020, 73(1):130-139. doi: S0168-8278(20)30119-7 pmid: 32145258
[35]	Cartin-Ceba R, Halank M, Ghofrani HA, et al. Riociguat treatment for portopulmonary hypertension: A subgroup analysis from the PATENT-1/-2 studies[J]. Pulm Circ, 2018, 8(2):2045894018769305.
[36]	Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): A multicentre, open-label, randomised controlled trial[J]. Lancet Respir Med, 2021, 9(6):573-584.
[37]	Melgosa MT, Ricci GL, García-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension[J]. Liver Transpl, 2010, 16(3):348-356.
[38]	Onoe T, Tanaka A, Ishiyama K, et al. Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: A case report[J]. Surg Case Rep, 2018, 4(1):15. doi: 10.1186/s40792-018-0423-6 pmid: 29417353
[39]	Krowka MJ, Fallon MB, Kawut SM, et al. International liver transplant society practice guidelines: Diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension[J]. Transplantation, 2016, 100(7):1440-1452. doi: 10.1097/TP.0000000000001229 pmid: 27326810
[40]	中华医学会器官移植学分会围手术期管理学组, 中国医师协会外科医师分会器官移植围手术期管理专业委员会. 门静脉性肺动脉高压肝移植围手术期管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2022, 21(1):10-14.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 40

Related Articles 1

Recommended Articles

Metrics

Comments